Telix submits European marketing application for brain cancer imaging agent
Telix Pharmaceuticals has lodged a marketing authorisation application (MAA) with European regulators for its glioma imaging candidate TLX101-Px. The submission covers major European markets, with France’s National Agency for Medicines and Health Products Safety (ANSM) serving as Reference Member State to coordinate scientific evaluation across concerned jurisdictions.
The company has been preparing European and U.S. regulatory packages concurrently, bringing forward the European filing to meet an agreed date whilst aligning with aspects of the U.S. Food and Drug Administration (FDA) package. The submission seeks a broad clinical label reflective of current clinical practice guidelines, with a U.S. New Drug Application (NDA) resubmission to follow.
TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine, also known as 18F-FET) targets glioma, the most common primary brain tumour of the central nervous system. Subject to regulatory approval, the proposed European brand name is Pixlumi®. This marks a major regulatory filing for Telix’s brain cancer imaging portfolio, expanding beyond its established prostate cancer franchise into a high-unmet-need oncology segment.
Join thousands of readers who start here
Our best articles, sent straight to your inbox. You can unsubscribe anytime.
Understanding amino acid PET imaging in brain cancer
FET-PET imaging uses positron emission tomography to detect how brain tumours absorb amino acids, providing biological information about tumour activity. This differs from conventional magnetic resonance imaging (MRI), which relies primarily on structural changes and blood-brain barrier disruption.
Key limitations of conventional MRI include:
- Lack of biological specificity (cannot distinguish active tumour from other tissue changes)
- Dependency on blood-brain barrier disruption for contrast enhancement
- Inability to reliably differentiate tumour progression from treatment-related effects
- Inconclusive results that can delay time-sensitive treatment decisions
FET-PET addresses these gaps by targeting membrane transport proteins (LAT1 and LAT2) that are overexpressed in glioma cells. This biological specificity is particularly valuable in the post-treatment setting, where radiation therapy and chemotherapy can cause changes in brain tissue that mimic tumour progression on MRI scans. Clinicians describe this diagnostic uncertainty as a critical unmet need, given glioma’s low survival rates and the necessity for rapid treatment decisions.
Whilst FET-PET imaging is already used in European clinical practice, access is limited to hospital-based production at select sites. No generally available commercial product currently ensures consistent quality and widespread access across Europe.
The European glioma imaging opportunity
The addressable patient population in Europe is substantial. Gliomas represent a significant proportion of brain and central nervous system tumours, particularly among malignant cases that require urgent diagnostic clarity.
| Metric | Figure |
|---|---|
| Annual European brain/CNS tumour diagnoses | ~67,500 |
| Glioma proportion of diagnoses | ~30% |
| Glioma proportion of malignant brain tumours | Up to 80% |
The current access problem extends to both adult and paediatric populations. Subject to regulatory approval, TLX101-Px has the potential to enable patients across Europe to receive greater diagnostic clarity for treatment decision-making, with potential for additional future indications beyond the initial glioma label.
Strategic alignment with Telix’s glioblastoma therapy programme
The imaging submission forms part of a broader theranostic strategy targeting glioblastoma, the most aggressive form of glioma. TLX101-Px is being developed as a patient selection and response assessment tool for Telix’s investigational therapy candidate TLX101-Tx (iodofalan 131I).
Both products target the same biological pathway. TLX101-Px images LAT1 and LAT2 transporter expression, whilst TLX101-Tx delivers targeted radiation therapy to cells expressing these transporters. This creates a diagnostic-therapeutic ecosystem where imaging can identify suitable patients and monitor their response to treatment.
TLX101-Tx programme milestones:
- Orphan drug designation granted in both Europe and the U.S. for glioblastoma
- Phase 3 IPAX-BrIGHT trial (NCT07100730) launching in multiple European countries for recurrent glioblastoma
- Additional study IPAX-2 (NCT05450744) ongoing
Regulatory approval for TLX101-Px could accelerate patient recruitment and response monitoring for these therapy trials. The imaging agent would enable clinicians to confirm target expression before enrolling patients and assess whether treatment is working during the trial, potentially improving trial efficiency and data quality.
Neither TLX101-Px nor TLX101-Tx has received marketing authorisation in any jurisdiction. Both products remain investigational pending regulatory approval.
Expert perspective on clinical utility
The clinical rationale for FET-PET imaging in glioma management centres on the post-therapy setting, where diagnostic uncertainty is most acute. Independent neuroimaging experts have highlighted the potential for improved patient management through more confident treatment decision-making.
Philipp Lohmann
Group Leader Digital Translational Neuroimaging, Forschungszentrum Jülich“FET-PET imaging is already used in clinical practice in Europe for the evaluation of gliomas, and plays a critical role in treatment decision making. This applies particularly in the post-therapy setting, where conventional MRI alone can be limited in its ability to distinguish tumor progression from treatment-related changes. Having widespread access to TLX101-Px has potential to provide clinicians with greater biological insight, supporting more confident and timely management of patients with brain tumors.”
Enjoyed this article?
We publish high-impact stories like this a few times a week. No spam.
Regulatory pathway and next steps
The European MAA submission follows the European Decentralised Procedure, with ANSM coordinating evaluation in collaboration with concerned Member States representing major European markets. The concurrent preparation of European and U.S. regulatory packages has enabled the company to expedite the European filing whilst leveraging aspects of the FDA package for the additional application.
Regulatory sequence:
- European MAA submitted (18 February 2026)
- ANSM-led evaluation with concerned Member States
- U.S. NDA resubmission to follow
- Commercial launch subject to final approvals (proposed brand: Pixlumi®)
The submission was filed in accordance with a pre-defined date agreed with European regulators. This dual-market regulatory strategy positions Telix for potential approvals in two of the world’s largest pharmaceutical markets, with the staggered approach allowing learnings from the European review process to inform the subsequent U.S. filing.
For the U.S. market, this represents a resubmission following previous regulatory feedback. The company has indicated it is utilising aspects of its FDA package to support both applications.
Management commentary
Chief Executive Officer Kevin Richardson emphasised the strategic importance of the submission for Telix’s broader brain cancer development programme. The regulatory milestone is positioned to establish widespread glioma imaging infrastructure that could support the company’s corresponding therapeutic development activities.
Kevin Richardson
Chief Executive Officer, Telix Precision Medicine“We see a compelling opportunity in Europe to broaden access to authorized targeted radiopharmaceuticals for brain cancer imaging and therapy, and as such this submission is an important milestone for Telix. The strategic value of this submission is particularly relevant to establishing widespread glioma imaging as part of our corresponding therapeutic development program. We have been able to utilize aspects of our FDA package to expedite the European filing, which has been submitted in accordance with a pre-defined date agreed with the regulator, with the U.S. resubmission to follow.”
The company aims to expand patient access to advanced brain imaging that can distinguish progressive or recurrent glioma from treatment-related changes, with the imaging approval serving as a foundation for its broader brain cancer therapy ambitions in both European and U.S. markets.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to receive market-moving announcements the moment they drop—before the crowd reacts.